STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score

Gomes, Inês M.; Arinto, Patrícia; Lopes, Carlos; Santos, Cecília R. A.; Maia, Cláudio J.

doi:10.1016/j.urolonc.2013.08.028

Cited by 57 publications

(73 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it is well characterized that STEAP1 is overexpressed in PCa, and normal prostatic tissues preferentially located on the plasma membrane of epithelial cells, particularly on cell-cell junctions, and to a lesser extend dispersed on the cytoplasm [5]. This overexpression relates adenocarcinoma and prostatic intraepithelial neoplasia scores suggest that STEAP1 could be involved in tumor initiation and progression and may be of clinical usefulness in early disease diagnosis [6]. STEAP1 can serve as a biomarker of worse prognosis because of its association with higher Gleason score, seminal vesicle invasion, biochemical recurrence, and worse outcome (metastasis or PCa-specific death) [6,7].…”

Section: Steap1 In Prostate Cancer: a Model Of Knowledge Developmentmentioning

confidence: 99%

STEAP-1: A Potential Biomarker, Promising Target?

Elm’hadi¹,

Errihani²,

Ichou³

2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

STEAP1 is one of six-transmembrane epithelial antigen of prostate (STEAP) highly expressed in human prostate cancer and is up-regulated in multiple cancers, including bladder, colon, breast, Ewing and lung cancers. Immunohistochemical analysis demonstrates significant STEAP1 expression at the intercellular communication between adjacent cells suggesting that this antigen must be a channel, or a transport protein indicating its potential role in tumor cell intercellular communication increasing the potential of STEAP1 as a diagnostic, prognostic, prophylactic and/or therapeutic target for new immunotherapeutic strategies. In prostate cancer, overexpression relates adenocarcinoma and prostatic intraepithelial neoplasia scores suggest that STEAP1 could be involved in tumor initiation and progression and may be of clinical usefulness in early disease diagnosis. Also, STEAP1 can serve as a biomarker of worse prognosis because of its association with higher Gleason score, seminal vesicle invasion, biochemical recurrence, and worse outcome. Therapeutically, STEAP1 is one of a few prostate cancer antigens that meet the appropriate criteria and represent an attractive target for antibody cancer therapy. It can be a target of anti-tumor CD8, or serve as a tool for vaccination as shown by xenograft models and phases I/II studies. STEAP1 could also serve as a new marker of tumor angiogenesis in lung cancer, indicate for occult residual tumor cells in patients with Ewing Sarcoma and also be used as a cell surface antigen for the development of breast cancer immunotherapy. The standardization of its evaluation as well as the validation through randomized trials would be necessary.

show abstract

Section: Steap1 In Prostate Cancer: a Model Of Knowledge Developmentmentioning

confidence: 99%

STEAP-1: A Potential Biomarker, Promising Target?

Elm’hadi¹,

Errihani²,

Ichou³

2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

show abstract

“…The first route is characterized by strong upregulation of the TGF-β receptor ALK1, which can be activated by various BMPs, in addition to TGF-β1 and TGF-β3 [41,42]. Inhibition of ALK1 in our model led to reduced phosphorylation of p38, downregulation of the EMT-markers VIM, MMP1, CDH2, and SNAI2, as well as reduced expression of ID1 and ID2, for which induction by ALK1 signaling is known [43]. ALK1-induced expression of ID1 promotes tumor cell metastasis [44].…”

Section: Discussionmentioning

confidence: 75%

“…TOP2B) and subsequent recombination suggesting a non-random chromosomal rearrangement in PCa [40,42,43]. In response to genotoxic stress, AR also recruits activation-induced cytidine deaminase (AID) and the LINE-1 encoded endonuclease ORF2 that promote genomic rearrangements [42].…”

Section: The Pathogenesis and Progression Of Prostate Cancermentioning

confidence: 99%

“…JMJD1C has been described as coactivator for several transcription factors including AR [41,42]. A general interaction between Jmj-containing KDM proteins and ERG has been reported to lead to activation of the YAP1 proliferation pathway [43]. JMJD1C expression has further been implicated in the reactivation of silenced genes in diverse tissues and cancer [44].…”

Section: Microarray Profiling Indicates Differentially Expressed Epigmentioning

confidence: 99%

“…Genes showing >|1.3| fold change compared to control were considered as significantly differentially regulated and used for further analysis using the Ingenuity Pathway analysis (IPA) tool (Supplementary Table S4 Table S4.5) and RNA-seq data in NEPC [2] revealed consistent differential expression, including the genes STEAP1, ALDH1A3, HEPACAM2, and E2F2. For example, ALDH1A3, an AR-regulated gene [40][41][42], and STEAP1, suggested as a marker of prostate adenocarcinoma [43,44], were higher expressed in prostate adenocarcinoma samples compared to NEPC tissue [2] and were upregulated upon INSM1 knockdown.…”

Section: Insm1 Induces a Ne Molecular Signature In Pca Cellsmentioning

confidence: 99%

See 2 more Smart Citations

A Prominent Couple

Ratz¹

View full text Add to dashboard Cite

Six‐transmembrane epithelial antigen of the prostate 1 is associated with tumor invasion and migration in endometrial carcinomas

Sun

Xie

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a member of the STEAP family, is a general tumor antigen. However, no information has been available to date regarding the function of STEAP1 in the progression of endometrial carcinoma. In this study, we used in vitro and in vivo strategies to prove that STEAP1 plays an important role in the progression of endometrial carcinoma. Immunohistochemistry, immunocytochemistry, quantitative reverse transcription polymerase chain reaction (RT-qPCR), and Western blot analysis were used to detect the expression of STEAP1 in normal endometrial cells and endometrial cancer cell lines. The progression of the cell cycle, plate clone formation assay, and transwell migration and invasion assays were performed to examine the effects of STEAP1 on cell proliferation, clonogenicity, migration, and their invasive capacity. In addition, we confirmed that STEAP1 was tightly correlated with the development of tumor in vivo. The relationship between epithelial to mesenchymal transition (EMT) and STEAP1 expression was evaluated by RT-qPCR and Western blot analysis. Matrix metalloproteinase (MMP) zymography assay was used to detect the activities of MMP2 and MMP9. STEAP1 was restrictively expressed in endometrial carcinoma and downregulation of the STEAP1 gene increased proliferation and clonogenicity, as well as promoted cell migration, invasion, and the progress of EMT. STEAP1 is downregulated in endometrial carcinoma and can restrict migration and invasion of endometrial carcinoma cells. Overall, STEAP1 may be an ideal target for tumor therapy and diagnosis in the future. K E Y W O R D S endometrial carcinoma, epithelial to mesenchymal transition, invasion, migration, six-transmembrane epithelial antigen of the prostate 1A standard streptavidin-biotin-peroxidase staining procedure was used, wherein formalin-fixed, paraffin-embedded endometrial tissues were cut into 5-μm slices. After a series of processing steps, such as dewaxing in xylene, rehydration, and antigen retrieval, sections were incubated with the mouse anti-human STEAP1 monoclonal antibody (ab117454; Abcam) at a dilution of 1﹕200 . Six-transmembrane epithelial antigen of the prostate 1 is associated with tumor invasion and migration in endometrial carcinomas.

show abstract

STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score

Cited by 57 publications

References 25 publications

STEAP-1: A Potential Biomarker, Promising Target?

STEAP-1: A Potential Biomarker, Promising Target?

A Prominent Couple

Six‐transmembrane epithelial antigen of the prostate 1 is associated with tumor invasion and migration in endometrial carcinomas

Contact Info

Product

Resources

About